Results from IVANOS, a study evaluating Cerapedics’ i-FACTOR™ Peptide Enhanced Bone Graft in lumbar posterolateral spine surgery, demonstrated a 50% fusion rate in i-FACTOR patients vs. 20% fusion rate with allograft at one-year post-op.
The single-center, double-blind, randomized study treated 240 levels in 98 patients with lumbar spinal stenosis and accompanying degenerative olisthesis.
In the lumbar region, Cerapedics is also conducting an Investigational Device Exemption clinical trial of P-15L Peptide Enhanced Bone Graft vs. autograft in transforaminal lumbar interbody fusion to treat degenerative disc disease.
Results from IVANOS, a study evaluating Cerapedics' i-FACTOR™ Peptide Enhanced Bone Graft in lumbar posterolateral spine surgery, demonstrated a 50% fusion rate in i-FACTOR patients vs. 20% fusion rate with allograft at one-year post-op.
The single-center, double-blind, randomized study treated 240 levels in 98 patients with lumbar spinal...
Results from IVANOS, a study evaluating Cerapedics’ i-FACTOR™ Peptide Enhanced Bone Graft in lumbar posterolateral spine surgery, demonstrated a 50% fusion rate in i-FACTOR patients vs. 20% fusion rate with allograft at one-year post-op.
The single-center, double-blind, randomized study treated 240 levels in 98 patients with lumbar spinal stenosis and accompanying degenerative olisthesis.
In the lumbar region, Cerapedics is also conducting an Investigational Device Exemption clinical trial of P-15L Peptide Enhanced Bone Graft vs. autograft in transforaminal lumbar interbody fusion to treat degenerative disc disease.
Copy to clipboard 
